Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Neoadjuvant terapi (Tx) för Merkelcellskarcinom med PD-1-hämmaren Cemiplimab (NeoMatryx)

Neoadjuvant terapi (Tx) för Merkelcellscancer med PD-1-hämmaren Cemiplimab - En randomiserad, dubbelblind, placebokontrollerad, icke-jämförande fas II-studie

The study is a randomized, double blind, placebo-controlled, non-comparative phase II trial that investigates the efficacy of neoadjuvant anti-PD-1 antibody Cemiplimab treatment in patients with clinical stage I or II Merkel cell carcinoma who have have undergone primary tumour excision and are pending sentinel lymph node biopsy.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

135

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

    • Baden-Wurttemberg
      • Heidelberg, Baden-Wurttemberg, Tyskland, 69120
        • Rekrytering
        • Nationales Centrum für Tumorerkrankungen
        • Kontakt:
          • Jessica Hassel, Prof. Dr.
      • Mannheim, Baden-Wurttemberg, Tyskland, 68161
        • Rekrytering
        • Universitätsklinikum Mannheim
        • Kontakt:
          • Jochen Utikal, Prof. Dr.
      • Tübingen, Baden-Wurttemberg, Tyskland, 72076
        • Rekrytering
        • Universitätsklinikum Tübingen
        • Kontakt:
          • Ulrike Leiter-Stöppke, Prof. Dr.
    • Bavaria
      • Regensburg, Bavaria, Tyskland, 93053
        • Rekrytering
        • Universitätsklinikum Regensburg
        • Kontakt:
          • Sebastian Haferkamp, Prof. Dr.
      • Würzburg, Bavaria, Tyskland, 97080
        • Rekrytering
        • Universitätsklinikum Würzburg
        • Kontakt:
          • Anja Gieserich, Dr.
    • Free and Hanseatic City of Hamburg
      • Hamburg, Free and Hanseatic City of Hamburg, Tyskland, 20246
        • Rekrytering
        • Universitätsklinikum Hamburg-Eppendorf
        • Kontakt:
          • Christoffer Gebhardt, Prof. Dr.
    • Hesse
      • Frankfurt am Main, Hesse, Tyskland, 60590
        • Rekrytering
        • Universitätsklinikum Frankfurt
        • Kontakt:
          • Bastian Schilling, Prof. Dr.
    • North Rhine-Westphalia
      • Bielefeld, North Rhine-Westphalia, Tyskland, 33647
        • Rekrytering
        • Klinikum Bielefeld
        • Kontakt:
          • Selma Ugurel, Prof. Dr.
      • Essen, North Rhine-Westphalia, Tyskland, 45147
        • Rekrytering
        • Universitätsklinikum Essen
        • Kontakt:
          • Dirk Schadendorf, Prof. Dr.
      • Minden, North Rhine-Westphalia, Tyskland, 32429
        • Har inte rekryterat ännu
        • Johannes Wesling Klinikum Minden
        • Kontakt:
          • Ralf Gutzmer, Prof. Dr.
    • Rhineland-Palatinate
      • Mainz, Rhineland-Palatinate, Tyskland, 55131
        • Rekrytering
        • Universitätsmedizin Mainz
        • Kontakt:
          • Stefan Grabbe, Prof. Dr.
    • Thuringia
      • Erfurt, Thuringia, Tyskland, 99089
        • Rekrytering
        • Helios Klinikum Erfurt
        • Kontakt:
          • Rudolph Herbst, Prof. Dr.

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion criteria

  1. Patient has signed informed written consent.

  2. Patients is 18 years and older at time of signing of written informed consent

  3. Patient has diagnosis of Merkel cell carcinoma in clinical stage II, or in stage I with minimum diameter of 1 cm, with primary tumor already removed and a planned sentinel lymph nodes biopsy still pending.

  4. Patient has ECOG performance status 0-2.

  5. Patients has adequate laboratory parameters particularly for the blood count, renal and liver function parameters.

    1. Absolute number of neutrophils ≥ 1.5 x 109/L
    2. Platelets ≥ 75 x 109/L
    3. Hemoglobin ≥ 9 g/dL
    4. Total bilirubin ≤ 1.5 times the upper limit of normal (ULN) (patients with Gilbert´s Disease and total bilirubin up to 3x ULN may be eligible after approval from trial's medical expert)
    5. AST (SGOT) and ALT (SGPT) ≤ 3x ULN
    6. AP ≤ 2.5x ULN
    7. Serum creatinine ≤ 2x ULN or creatinine clearance ≥ 40 mL/min
  6. Female patients of childbearing potential and male patients with female partners of childbearing potential must agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 6 months after the last dose of Cemiplimab. Male patients must refrain from donating sperm during this same period. Male patients with a pregnant partner must agree to remain abstinent or to use a condom for the duration of the pregnancy.

  7. Patient must be willing to allow translational work-up of tissue samples (PT, sentinel lymph node biopsy).

Exclusion criteria

  1. Patient has prior sentinel lymph node removal for the current MCC.

  2. Patients received prior treatment with immunotherapy (such as PD-1/PD-L1 or CTL4) or any other systemic anti-tumor (MCC) therapy (incl. investigational therapies)

  3. Patient has active or a history of hematological neoplasms including chronic lymphocytic leukemia (CLL), irrespective if these require treatment or not.

  4. Patient had prior organ transplantation including allogenic stem-cell transplantation.

  5. Patient receives immunosuppressive concomitant medication, EXCEPT for the following:

    i. Intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection).

    ii. Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent.

    iii. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).

  6. Patient has known hypersensitivity to any component of the Cemiplimab formulation as well as a known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion protein.

  7. Patient has active autoimmune or inflammatory disorders.

  8. Patient has history of interstitial lung disease.

  9. Patient has active infection requiring systemic therapy.

  10. Patient has Active infection requiring systemic therapy, including uncontrolled HIV, HBV and HCV infection or diagnosis of immunodeficiency.

    NOTE: Patients are eligible if:

    • Patients have controlled HIV infection with CD4 counts is > 350 cells/μL and viral load is undetectable [HIV RNA PCR]. Patients with controlled HIV infection must be monitored per local standards during the trial.
    • Patients positive for HBV surface antigen have controlled HBV infection receiving anti-viral therapy and with undetectable serum viral load [HBV DNA PCR]. Patients with controlled infection must undergo periodic monitoring of HBV DNA and p must remain on anti-viral therapy for at least 6 months after last dose of Cemiplimab.
    • Patients positive for HCV antibody have controlled HCV infection with undetectable viral load [HCV RNA PCR].
  11. Patent received vaccination with any live vaccine (e.g., intranasal flu vaccine) within 4 weeks before the first dose of Cemiplimab or planned vaccination with live vaccine during the trial

  12. Female patients, who are pregnant or breast feeding or planning to become pregnant within and 6 months after the end of treatment. Female patients of childbearing potential must have a negative serum β-HCG pregnancy test result within 7 days prior to initiation of study treatment.

  13. Patient has evidence of any other disease, neurologic or metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of any of the study medications, puts the patient at higher risk for treatment-related complications or may affect the interpretation of study results.

  14. Patient has known substance abuse or other psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results

  15. Patient is legally incapacitated or has limited legal capacity

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Fyrdubbla

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Arm A (Cemiplimab)

2 cycles of Cemiplimab (350 mg, i.v., Q3W) followed by sentinel lymph node biopsy

Patients will receive Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles

Andra namn:
  • LIBTAYO
Placebo-jämförare: Arm B (placebo)

2 cycles of placebo followed by sentinel lymph node biopsy

Patients will receive NaCl 0.9% solution i.v. on day 1 of every 21 days cycle for 2 cycles.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Nodal micrometastases-free rate
Tidsram: up to 36 months

rate of patients without nodal micrometastases after 2 cycles of treatment, determined by sentinel lymph node biopsy

up to 36 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Recurrence-free survival
Tidsram: up to 66 months

time from randomization until date of the first of the following events: MCC recurrence, and MCC-related death

up to 66 months
Time to recurrence
Tidsram: up to 66 months

defined as time from randomization until date of first MCC recurrence

up to 66 months
Overall survival
Tidsram: up to 66 months

time from randomization until date of death from any cause

up to 66 months
Quality of life using FCRI-SF questionnaire
Tidsram: up to 66 months

Quality of life determined using the FCRI-SF questionnaire

up to 66 months
Safety (AEs and SAEs)
Tidsram: up to 66 months

incidence, nature, causality, frequency, timing and severity of adverse events using NCI CTCAE 5

up to 66 months
Disease specific survival
Tidsram: up to 66 months

time from randomization until date of MCC-related death

up to 66 months
Quality of life using the mFACT-M questionnaire
Tidsram: up to 66 months

Quality of life determined using the mFACT-M questionnaire

up to 66 months

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Investigation of prognostic and predictive biomarkers to estimate the risk of lymph node metastases and signs of immune activation in the sentinel lymph nodes
Tidsram: up to 66 months

Biosamples will be used to determine the correlation of identified biomarkers with clinical outcome, i.e., nodal metastases-free rate, RFS, OS

up to 66 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studierektor: Salah Al-Batran, Prof. Dr., Institut für Klinische Krebsforschung IKF GmbH
  • Huvudutredare: Ralf Gutzmer, Prof. Dr. med., Johannes Wesling Klinikum Minden
  • Huvudutredare: Juergen C. Becker, Prof. Dr. Dr., Translational Skin Cancer Research University Duisburg-Essen, Germany

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

29 maj 2026

Primärt slutförande (Beräknad)

31 december 2029

Avslutad studie (Beräknad)

31 juli 2031

Studieregistreringsdatum

Först inskickad

28 januari 2026

Först inskickad som uppfyllde QC-kriterierna

28 januari 2026

Första postat (Faktisk)

4 februari 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

9 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

4 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera